RE:RE:RE:RE:FDA decision will have waterfall effect on other companiesOuch! Paid content from Promis doesn't count as an article.
This scenario was so completely contrived by our consultants. These bozos could have gone the opposite direction by forecasting Aducanumab's failure and then we'd be in a win-win situation regardless of the FDA panel review. They chose instead to put our money into an excuse for their promotional failures, and now you're playing into their game.